CAR T Cell Therapy for Non-Hodgkin's Lymphoma (NHL) Market

1. Chimeric Antigen Receptor T Cell (CAR- T) Therapy for Non-Hodgkin’s Lymphoma (NHL) Market Chimeric antigen receptor (CAR) T-cell therapy involves genetic modification of patient’s autologous T-cells to express a CAR, specific for a tumor antigen, followed by ex vivo cell expansion and re-infusion back to the patient. CAR T-cells are the fusion proteins of a selected single-chain fragment variable from a specific monoclonal antibody and one or more T-cell receptor intracellular signaling domains. A CAR combines antigen-binding domains-most commonly, a single-chain variable fragment (scFv) derived from the variable domains of antibodies with the signalling domains of the TCR chain and additional costimulatory domains from receptors, such as CD28, OX40, and CD137 (Morgenstern & Irwin, 2019). T-cell genetic modification may occur either via viral-based gene transfer methods or non-viral methods, such as DNA-based transposons, CRISPR/Cas9 technology, zinc finger nuclease (ZFN), transcription activator-like effector nuclease (TALEN), or direct transfer of in vitro transcribed-mRNA by electroporation. DelveInsight’s ‘CAR T-Cell Therapy for Non-Hodgkin’s lymphoma (NHL) - Market Insights and Market Forecast-2030’ report delivers an in-depth understanding of the CAR T-Cell Therapy for Non-Hodgkin’s lymphoma (NHL) and market trends in the 6MM, i.e., United States and EU5 (Germany, Spain, Italy, France and United Kingdom). The CAR T-Cell Therapy for Non-Hodgkin’s lymphoma (NHL) market report provides current treatment practices, emerging therapies, CAR T-Cell Therapy for Non-Hodgkin’s

2. lymphoma market share of the individual therapies, current and forecasted CAR T-Cell Therapy for Non-Hodgkin’s lymphoma market size from 2017 to 2030 segmented by US and EU markets. The Report also covers current CAR T-Cell Therapy for Non- Hodgkin’s lymphoma treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses underlying potential of the market. Click here to view the report: https://www.delveinsight.com/report-store/car-t- cell-therapy-for-non-hodgkins-lymphoma-market Geography Covered The United States EU5 (Germany, France, Italy, Spain and the United Kingdom) Study Period: 2017–2030 CAR T-Cell Therapy for Non-Hodgkin’s lymphoma (NHL) Disease Understanding and Treatment Algorithm CAR T-Cell Therapy for Non-Hodgkin’s lymphoma (NHL) Overview Chimeric antigen receptor (CAR) T-cell therapy involves genetic modification of patient’s autologous T-cells to express a CAR, specific for a tumor antigen, followed by ex vivo cell expansion and re-infusion back to the patient. CAR T-cells are the fusion proteins of a selected single-chain fragment variable from a specific monoclonal antibody and one or more T-cell receptor intracellular signaling domains. NHL is another type of blood cancer affecting the lymphocytes that witness high number of relapse cases. Diffuse large B-cell lymphoma (DLBCL) is the most common type of NHL, accounting for about 22% of newly diagnosed cases of B-cell NHL in the United States. Request for sample pages: https://www.delveinsight.com/sample-request/car-t- cell-therapy-for-non-hodgkins-lymphoma-market CAR T-Cell Therapy for Non-Hodgkin’s lymphoma (NHL) Treatment It covers the details of conventional and current medical therapies available as the CAR T-Cell Therapy in Non-Hodgkin’s lymphoma market for the treatment of this condition. It also provides the country-wise treatment guidelines and algorithm across the United States and Europe. The DelveInsight CAR T-Cell Therapy for Non-Hodgkin’s lymphoma market report gives a thorough understanding of CAR T-Cell Therapy for Non-Hodgkin’s lymphoma (NHL) by including details such as disease definition, symptoms, causes, pathophysiology,

3. and diagnosis. It also provides treatment algorithms and treatment guidelines for Non- Hodgkin’s lymphoma (NHL) in the US and Europe. CAR T-Cell Therapy for Non-Hodgkin’s lymphoma (NHL) Epidemiology Insights NHL is another type of blood cancer affecting the lymphocytes that witnesses high number of relapse cases. Diffuse large B-cell lymphoma (DLBCL) is the most common type of NHL, accounting for about 22% of newly diagnosed cases of B-cell NHL in the United States. B-cell lymphomas consist of around 85% of all NHL cases that are diagnosed in the United States. CAR T-Cell Therapy for Non-Hodgkin’s lymphoma (NHL) Drug Chapters Drug chapter segment of the CAR T-Cell Therapy for Non-Hodgkin’s lymphoma report encloses the detailed analysis of Non-Hodgkin’s lymphoma marketed CAR T-Cell Therapies and late stage (Phase-III and Phase-II) pipeline therapies. It also helps to understand the CAR T-Cell Therapy for Non-Hodgkin’s lymphoma (NHL) clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included therapy and the latest news and press releases. Download sample pages: https://www.delveinsight.com/sample-request/car-t-cell- therapy-for-non-hodgkins-lymphoma-market CAR T-Cell Therapy for Non-Hodgkin’s lymphoma (NHL) Marketed Therapies 1. Kymriah (tisagenlecleucel): Novartis Kymriah (tisagenlecleucel), formerly known as CTL019, is a prescription cancer treatment approved for the use in patients up to 25 years old who have r/r ALL that and adult patients with r/r large B-cell lymphoma after two or more lines of systemic therapy including DLBCL not otherwise specified, high grade B-cell lymphoma and DLBCL arising from follicular lymphoma. Products detail in the report… CAR T-Cell Therapy for Non-Hodgkin’s lymphoma (NHL) Emerging Therapies 1. KTE-X19: Gilead Sciences KTE-X19 is an investigational CD19 CAR T-cell therapy. KTE-X19 has the same construct as axicabtagene ciloleucel; however, the manufacturing process for KTE-X19 differs from that of axicabtagene ciloleucel and includes the enrichment of lymphocytes. Lymphocyte enrichment is necessary in certain B-cell malignancies for which KTE-X19 in under investigation. KTE-X19 is currently in Phase I/II trials in acute lymphoblastic

4. leukemia (ALL) and chronic lymphocytic leukemia (CLL). And phase II in Relapsed/Refractory Mantle Cell Lymphoma. Products detail in the report… CAR T-Cell Therapy for Non-Hodgkin’s lymphoma (NHL) Market Outlook Non-Hodgkin’s lymphoma (NHL) comprises a heterogeneous group of proliferative malignancies that arise in the B cells, T cells, or natural killer (NK) cells within the lymphoid tissue, such as the lymph nodes, bone marrow, thymus, and spleen. B-cell lymphomas comprise approximately 85% of all NHL cases diagnosed in the US, and are a diverse group of blood cancers that arise in the B-cells. The CAR T-Cell Therapy for Non-Hodgkin’s lymphoma (NHL) market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted Non-Hodgkin’s lymphoma market trends by analyzing the impact of current CAR T-Cell Therapies on the market, unmet needs, drivers and barriers and demand of better technology. This segment gives a thorough detail of Non-Hodgkin’s lymphoma market trend of each marketed CAR T-Cell Therapy and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight. According to DelveInsight, CAR T-Cell Therapy for Non-Hodgkin’s lymphoma market in 6MM is expected to change in the study period 2017–2030. Download report: https://www.delveinsight.com/report-store/car-t-cell-therapy- for-non-hodgkins-lymphoma-market Access to sample pages: https://www.delveinsight.com/sample-request/car-t-cell- therapy-for-non-hodgkins-lymphoma-market About DelveInsight: DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.